Percorrer por autor "Gil-Gouveia, Raquel"
A mostrar 1 - 10 de 34
Resultados por página
Opções de ordenação
- Alterations of white matter microstructure in migraine patients vary in the peri-ictal phasesPublication . Fouto, Ana R.; Nunes, Rita G.; Guadilla, Irene; Ruiz-Tagle, Amparo; Esteves, Inês; Caetano, Gina; Silva, Nuno A.; Vilela, Pedro; Gil-Gouveia, Raquel; Figueiredo, PatriciaAlterations in white matter (WM) microstructure are commonly found in migraine patients. Here, we employ a longitudinal study of episodic migraine without aura using diffusion magnetic resonance imaging (dMRI) to investigate whether such WM microstructure alterations vary through the different phases of the pain cycle. Fourteen patients with episodic migraine without aura related with menstruation were scanned through four phases of their (spontaneous) migraine cycle (interictal, preictal, ictal, and postictal). Fifteen healthy controls were studied in the corresponding phases of the menstrual cycle. Multishell dMRI data were acquired and preprocessed to obtain maps of diffusion parameters reflecting WM microstructure. After a whole-brain analysis comparing patients with controls, a region-of-interest analysis was performed to determine whether the patients’ microstructural changes varied across the migraine cycle in specific WM tracts. Compared with controls, patients showed reduced axial diffusivity (AD) in several WM tracts across the whole brain in the interictal phase and increased fractional anisotropy (FA) in commissural fibers in the ictal phase. Interestingly, AD returned to baseline levels during peri-ictal phases in specific projection and association fibers. In contrast, FA values decreased in the ictal phase away from normal values in a few commissural and projection tracts. Widespread WM fiber tracts suffer structural variations across the migraine cycle, suggesting microstructural changes potentially associated with limbic and salience functional networks and highlighting the importance of the cycle phase in imaging studies of migraine.
- CGRP-targeted medication in chronic migraine - systematic reviewPublication . Oliveira, Renato; Gil-Gouveia, Raquel; Puledda, FrancescaBACKGROUND: Chronic migraine is a highly debilitating condition that is often difficult to manage, particularly in the presence of medication overuse headache. Drugs targeting the calcitonin gene-related peptide (CGRP), or its receptor have shown promising results in treating this disorder. METHODS: We searched Pubmed and Embase to identify randomized clinical trials and real-world studies reporting on the use of medication targeting the calcitonin gene-related peptide in patients with chronic migraine. RESULTS: A total of 270 records were identified. Nineteen studies qualified for the qualitative analysis. Most studies reported on monoclonal antibodies targeting CGRP (anti-CGRP mAbs), that overall prove to be effective in decreasing monthly migraine days by half in about 27.6-61.4% of the patients. Conversion from chronic to episodic migraine was seen in 40.88% of the cases, and 29-88% of the patients stopped medication overuse. Obesity seems to be the main negative predictor of response to anti-CGRP mAbs. There is no evidence to suggest the superiority of one anti-CGRP mAb. Despite the lack of strong evidence, the combination of anti-CGRP medication with onabotulinumtoxinA in chronic migraine is likely to bring benefits for resistant cases. Atogepant is the first gepant to demonstrate a significant decrease in monthly migraine days compared to placebo in a recent trial. Further, anti-CGRP mAb and gepants have a good safety profile. CONCLUSION: There is strong evidence from randomized trials and real-world data to suggest that drugs targeting CGRP are a safe and effective treatment for chronic migraine.
- Cognitive aging in migraine sufferers is associated with more subjective complaints but similar age-related decline: a 5-year longitudinal studyPublication . Martins, Isabel Pavão; Maruta, Carolina; Alves, Pedro Nacimento; Loureiro, Clara; Morgado, Joana; Tavares, Joana; Gil-Gouveia, RaquelObjectives and background: The effect of headache on cognitive performance is controversial, due to conflicting results obtained from studies in clinical or population settings. We aimed to understand if migraine and other headaches modify the rates of decline on different cognitive measures, during a 5-year interval. Design and method: A cohort of community dwelling adults (> 50 years) with migraine (MH), non-migraine headaches (NMH) and controls without headache (WoH), was assessed by a comprehensive neuropsychological battery with tests of memory, language and executive functions, repeated 5 years apart. Change in performance between baseline and reevaluation was compared between groups, and controlled for age, gender, literacy and depressive symptoms. Results: A total of 275 participants (78.5% WoH, 12.7% MH, 8.7% NMH) were reevaluated (average age 70.40 + 8.34 years, 64% females). Cognitive decline or dementia occurred in 11.4%, with a similar proportion among the three groups. Although MH participants had significantly more subjective cognitive complaints (p = 0.030, 95%CI:]-3.929,-0.014[), both MH and NMH subjects showed an age-associated decline identical to controls. Furthermore, migraine features (disease and attack duration, frequency and aura) were unrelated with cognitive performance. Conclusion: Migraine and non-migraine headache are not associated with increasing risk of dementia or cognitive decline at an older age although subjects with migraine have more cognitive complaints. Longer longitudinal studies are necessary to understand if this pattern persists for more than 5 years.
- Cognitive performance along the migraine cycle: a negative exploratory studyPublication . Quadros, Maria Ana; Granadeiro, Marta; Ruiz-Tagle, Amparo; Maruta, Carolina; Gil-Gouveia, Raquel; Martins, Isabel PavãoMigraine patients frequently report cognitive difficulties in the proximity and during migraine attacks. We performed an exploratory comparison of executive functioning across the four stages of the migraine cycle. Consecutive patients with episodic migraine undertook cognitive tests for attention, processing speed, set-shifting, and inhibitory control. Performance was compared between patients in different migraine stages, controlling for attack frequency and prophylactic medication. One hundred forty-three patients (142 women, average age 36.2 ± 9.9 years) were included, 28 preictal (≤48 h before the attack), 21 ictal (during the attack), 18 postictal (≤24 h after attack), and 76 interictal. Test performance (age and literacy adjusted z-scores) was not significantly different across migraine phases, despite a tendency for a decline before the attack. This negative study shows that cognitive performance fluctuates as patients approach the attack. To control for individual variability, this comparison needs to be better characterized longitudinally with a within-patient design.
- Correction to: The role of community pharmacists in managing common headache disorders, and their integration within structured headache services: position statement on behalf of the European Headache Federation (EHF) and Lifting The Burden (LTB: the Global Campaign against Headache), with the formal endorsement of the International Pharmaceutical Federation (The Journal of Headache and Pain, (2025), 26, 1, (100), 10.1186/s10194-025-02021-3)Publication . Banihani, Heba; Lampl, Christian; Maassenvandenbrink, Antoinette; Amin, Faisal Mohammad; Carlsen, Louise Ninett; Coppola, Gianluca; Deligianni, Christina; Gil-Gouveia, Raquel; Holland, Philip R.; Husoy, Andreas K.; Jensen, Rigmor; Plácido, Madalena; Reuter, Uwe; Ryliskiene, Kristina; Rio, Margarita Sanchez del; Schytz, Henrik Winther; Tronvik, Erling; Versijpt, Jan; Steiner, Timothy J.Correction: J Headache Pain 26, 100 (2025) In this article, the text “on behalf of the European Headache Federation, the Norwegian Centre for Headache Research (NorHead) and Lifting The Burden: the Global Campaign against Headache” has been removed from the author list because it erroneously duplicated text from the article title.
- Cranial autonomic symptoms and neck pain in differential diagnosis of migrainePublication . Vicente, Beatriz Nunes; Oliveira, Renato; Martins, Isabel Pavão; Gil-Gouveia, RaquelCranial autonomic symptoms and neck pain have been reported to be highly prevalent in migraine, although they are rarely considered in clinical evaluation. The aim of this review is to focus on the prevalence, pathophysiology, and clinical characteristics of these two symptoms, and their importance in the differential diagnosis between migraines and other headaches. The most common cranial autonomic symptoms are aural fullness, lacrimation, facial/forehead sweating, and conjunctival injection. Migraineurs experiencing cranial autonomic symptoms are more likely to have more severe, frequent, and longer attacks, as well as higher rates of photophobia, phonophobia, osmophobia, and allodynia. Cranial autonomic symptoms occur due to the activation of the trigeminal autonomic reflex, and the differential diagnosis with cluster headaches can be challenging. Neck pain can be part of the migraine prodromal symptoms or act as a trigger for a migraine attack. The prevalence of neck pain correlates with headache frequency and is associated with treatment resistance and greater disability. The convergence between upper cervical and trigeminal nociception via the trigeminal nucleus caudalis is the likely mechanism for neck pain in migraine. The recognition of cranial autonomic symptoms and neck pain as potential migraine features is important because they often contribute to the misdiagnosis of cervicogenic problems, tension-type headache, cluster headache, and rhinosinusitis in migraine patients, delaying appropriate attack and disease management.
- Currículo básico em cefaleias para neurologistas: proposta da Sociedade Portuguesa de CefaleiasPublication . Parreira, Elsa; Machado, Sara; Gil-Gouveia, RaquelContinuous education in headaches is a priority for the Portuguese Headache Society. We present a proposal for a Core Curriculum in Headaches for Neurologists and Neurology-trainees, developed based on the ‘Headache Core Curriculum’ of the International Headache Society (IHS), revised in May 2020. This document is not merely a translation of the original but rather a structured adaptation to the national context, incorporating differences in the organization and structure of the content. Thus, this article presents the national proposal for the Core Curriculum in Headaches, while the annex includes the Portuguese translation of the original IHS document into Portuguese, which is also available on the IHS page (https://ihs-headache.org/en/learning-centre/ihs-core-curriculum/). In addition to the contents of each topic, the annex includes a list of recommended articles.
- Deciphering the mechanisms: pathophysiology of migraine-related cognitive dysfunctionPublication . Fernandes, Catarina; Gil-Gouveia, RaquelMigraine is increasingly understood as a disorder of brain network dysfunction, where attack-related cognitive symptoms (attention deficits, slowed processing speed and executive dysfunction) can be as disabling as pain and may persist into the interictal period. Such symptoms are associated with functional and structural changes across the migraine cycle, involving the prefrontal cortex, thalamus, hypothalamus, hippocampus and cerebellum. Interictal deficits in working memory, visuospatial processing, verbal fluency and executive function are also documented. Rodent models show impairments in learning and memory, while humans studies suggest that cortical hyperresponsiveness and deficient sensory habituation contribute to altered attentional processing, reflecting thalamocortical dysfunction and abnormal synaptic plasticity as underlying mechanisms. Cognitive performance is modulated by disease severity, chronification, hormonal fluctuations, psychiatric comorbidities, sleep disturbances and medication use. Anxiety, depression and sleep disorders negatively affect working memory, executive function and attention, while medication overuse further impairs visuospatial skills and orientation. Dementia risk appears heightened in migraine patients with frequent and severe attacks, as clinic-based studies consistently report cognitive deficits in this cohorts, unlike population-based studies. While longitudinal cohorts find no increased dementia risk, meta-analyses suggest a modest risk elevation. Differences are likely due to methodological differences in cognitive testing and diagnostic approaches. Cognitive dysfunction in migraine is multidimensional, involving intrinsic neuronal mechanism and external modulators, supporting the need for rational management strategies and treatment interventions.
- Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic reviewPublication . European Headache Federation, EHF; Gil-Gouveia, RaquelObjective To evaluate the long-term safety (≥12months) of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) or its receptor in migraine prevention by synthesising evidence from clinical trials and real-world studies. We focus on drug discontinuation due to adverse events and the type and frequency of adverse events. This is the first review to analyse the effects of the long-term use of all anti-CGRP (receptor) mAbs, aiming to provide novel insights for clinical practice and future treatment strategies. Methods We systematically searched PubMed, Cochrane Library, and ClinicalTrials.gov for studies with ≥12months of anti-CGRP (receptor) mAb use between January 2013 and April 2025. A random-effects meta-analysis of proportions (logit transformation, inverse variance weighting, restricted maximum likelihood) was performed to estimate pooled discontinuation and adverse event rates. Risk of bias was assessed using the ROBINS-I score. Results From a total of 1,499 records, 14met the inclusion criteria and were eligible for data analysis. These 14 records corresponded to 11 individual studies with observational durations all exceeding 12months. Seven studies investigated erenumab, two eptinezumab, and one each fremanezumab and galcanezumab. All studies were judged to have a severe risk of bias due to their underlying design. The overall pooled proportion of treatment discontinuation for any reason among patients receiving anti-CGRP (receptor) mAbs was 23%, whereas the pooled proportion of discontinuation specifically due to adverse events was substantially lower at 3%. Time-trend analysis showed that adverse event–related discontinuation remained low (<5%) beyond the first year, while overall adverse event incidence was high at baseline (>70%) but did not further increase with prolonged follow-up. Conclusion Evidence on long-term use of anti-CGRP (receptor) mAbs over 12months remains limited, but our analysis indicates good tolerability with consistently low adverse event-related discontinuation, no emergent safety signals, and largely non-serious, stable adverse event profiles. However, heterogeneity and study-level bias warrant
- Early use of erenumab vs nonspecific oral migraine preventives: the APPRAISE randomized clinical trialPublication . Pozo-Rosich, Patricia; Dolezil, David; Paemeleire, Koen; Stepien, Adam; Stude, Philipp; Snellman, Josefin; Arkuszewski, Michal; Stites, Tracy; Ritter, Shannon; Lopez, Cristina Lopez; Maca, Jeff; Ferraris, Matias; Gil-Gouveia, RaquelImportance: Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease burden. Objective: To compare the efficacy, tolerability, patient adherence, and patient satisfaction between erenumab and nonspecific oral migraine preventive medications (OMPMs) in patients with episodic migraine (EM) who had previously failed 1 or 2 preventive treatments. Design, Setting, and Participants: The 12-month prospective, interventional, global, multicenter, active-controlled, randomized clinical trial comparing sustained benefit of 2 treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (APPRAISE) trial was a 12-month open-label, multicenter, active-controlled, phase 4 randomized clinical trial conducted from May 15, 2019, to October 1, 2021. This pragmatic trial was conducted at 84 centers across 17 countries. Overall, participants 18 years or older with a 12-month or longer history of migraine, and 4 or more but fewer than 15 monthly migraine days (MMDs) were included. Interventions: Patients were randomized (2:1) to receive erenumab or OMPMs. Dose adjustment was permitted (label dependent). Main Outcomes and Measures: The primary end point was the proportion of patients completing 1 year of the initially assigned treatment and achieving a reduction of 50% or greater from baseline in MMDs at month 12. Secondary end points included the cumulative mean change from baseline in MMDs during the treatment period and the proportion of responders according to the Patients' Global Impression of Change (PGIC) scale at month 12 for patients taking the initially assigned treatment. Results: A total of 866 patients were screened, of whom 245 failed the screening and 621 completed the screening and baseline period. Of the 621 randomized patients (mean [SD] age, 41.3 [11.2] years; 545 female [87.8%]; 413 [66.5%] in the erenumab group; 208 [33.5%] in the OMPM group), 523 (84.2%) completed the treatment phase, and 98 (15.8%) discontinued the study. At month 12, significantly more patients assigned to erenumab vs OMPM achieved the primary end point (232 of 413 [56.2%] vs 35 of 208 [16.8%]; odds ratio [OR], 6.48; 95% CI, 4.28-9.82; P <.001). Compared with OMPMs, treatment with erenumab showed higher responder rate (314 of 413 [76.0%] vs 39 of 208 [18.8%]; OR, 13.75; 95% CI, 9.08-20.83; P <.001) on the PGIC scale (≥5 at month 12). Significant reduction in cumulative average MMDs was reported with erenumab treatment vs OMPM treatment (-4.32 vs -2.65; treatment difference [SE]: -1.67 [0.35] days; P <.001). Substantially fewer patients in the erenumab arm compared with the OMPM arm switched medication (9 of 413 [2.2%] vs 72 of 208 [34.6%]) and discontinued treatment due to adverse events (12 of 408 [2.9%] vs 48 of 206 [23.3%]). No new safety signals were identified. Conclusions and Relevance: Results of this randomized clinical trial demonstrated that earlier use of erenumab in patients with EM who failed 1 or 2 previous preventive treatments provided greater and sustained efficacy, safety, and adherence than continuous OMPM. Trial Registration: ClinicalTrials.gov Identifier: NCT03927144.